reports

Pfizer Utilizes Framework to Enable Quicker, More Effective Response to Major Societal Issues

Article

We live in challenging, often contentious times, with political, cultural and environmental issues constantly brewing. Companies across industries face the daunting task of appropriately responding to issues and news on a regular basis, and to help guide our responses at Pfizer, we developed our Social Framework – a way to determine if, when, how and why we will address a societal issue.

Pfizer Reaffirms Commitment to Delivering Essential Therapies Through Manufacturing Investment

Article

We are experiencing an exciting new era in drug discovery and development with scientific advances that could result in future breakthroughs. To make this promise a reality, Pfizer is dedicated to investing in manufacturing capabilities to keep pace with science today, and to plan for what’s coming next.

Pfizer Releases 2018 Annual Review

Article

Today, Pfizer released the 2018 Annual Review highlighting the ways that patients are the driving force behind every aspect of the company’s business in its mission to deliver innovative medicines and vaccines that help improve health and well-being at every stage of life.

This year, the integrated report explores how Pfizer’s work keeps Patients at Our Center. Highlights include:

Using the Science of Partnerships to Drive Patient Impact

Multimedia with summary

In Africa, patients can outnumber doctors 3,000 to 1. That’s one of the reasons why Pfizer is dedicated to fostering innovative partnerships that allow us to mobilize resources to help find new and unique solutions that increase access to needed health care.

Our colleague Willy Soriney, Strategic Partnership Director, works in Kenya using the science of partnerships to look for new approaches that can speed access to critical health interventions and fill unmet medical needs, bringing quality health care to those who need it most.

Tackling Antimicrobial Resistance with The Power of Science

Multimedia with summary

Antimicrobial resistance (AMR), or the ability of a bacterium, virus, or fungus to develop resistance to the medicines commonly used to treat them, is one of the leading global public health threats today. Currently, AMR causes more than 700,000 deaths annually. If left unchecked, this number is expected to rise to 10 million deaths annually by 2050. In collaboration with the infectious disease community, we are working to develop solutions that address and help treat the serious and growing AMR crisis.

Advancing The Power of Science Behind Immuno-Oncology

Multimedia with summary

Pfizer’s advances in oncology demonstrate the Power of Scientific innovation to help improve lives, particularly the power of Immuno-oncology (I-O). Immuno-oncology uses the natural ability of the body’s immune system to recognize and fight tumors. This past year, Pfizer continued to advance its work in I-O because we recognize the urgency of finding anti-cancer alternatives to help patients who need them.

Pfizer’s Progress on 2020 Reduced Water Use Goals

Multimedia with summary

Pfizer believes in the importance of reducing human impact on the environment. As part of this, the company has pledged to reduce water use by five percent by 2020.

See Pfizer’s progress toward reduced water consumption in our annual review at www.pfizer.com/annual.

 

Pfizer Is Accelerating the Supply Chain

Multimedia with summary

Through a Highly Orchestrated Supply Network (HOSuN) approach, Pfizer has developed a supply chain that is directly sensitive to patient needs and can speed our response to those needs. Enhanced with technological advances, we are able to track movement of product throughout the entire supply chain.

Pfizer Progress on 2020 Environmental Sustainability Goals

Blog

Pfizer has had two successful Greenhouse Gas (GHG) reduction goals which resulted in reductions of GHG emissions by roughly half from 2000 to 2014. We are working hard to meet our third GHG reduction goal to reduce emissions 20 percent further by 2020 from a 2012 baseline. This latest goal has been recognized as a Science Based Target by an initiative led by the Carbon Disclosure Project, the United Nations Global Compact, the World Resources Institute and the World Wildlife Fund.

Compared with a 2012 baseline, by the end of 2020 Pfizer has the goal to reduce:

Pages

Subscribe to reports